This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BOOK BY MIDNIGHT OCTOBER 29 TO SAVE $400!

  • 00
    DAYS
  • 00
    HRS
  • 00
    MINS
  • 00
    SECS
Delivered as a Hybrid Event from December 12 - 16, 2021
Live In-Person Experience Delivered December 12 - 16 2021Marriott Marquis San Diego

Kerry Chester, PhD
Professor of Molecular Medicine at UCL Cancer Institute

Profile

Kerry Chester is a Professor of Molecular Medicine at UCL and the CSO of NovalGen. She has over 25 years’ experience in antibody engineering and phage-display technology. Kerry has established academic GMP manufacturing for Phase I Trials and led development of novel antibodies for use as cancer imaging agents, recombinant antibody-enzyme fusion proteins, antibody drug conjugates and chimeric antigen receptors. She obtained her PhD from the University of London where she studied human antibody responses to cancer and she developed phage technology skills in Sir Greg Winter’s laboratory at Cambridge. Kerry is on the Board of Directors of The Antibody Society.

Agenda Sessions

  • A Clinical Stage ROR1xCD3 Bispecific Antibody with Potential for Broad Cancer Specificity

    2:30pm
  • Co-Chairs’ Remarks

    8:25am